MAM
Star Jalsha to wear a new ‘Diamond Star‘ logo
MUMBAI: Star Jalsha will unveil on 17 June a “refreshed” identity with a new diamond Star logo.
The logo will make its first appearance while airing the one-day fictionalised event, ‘Chalo Paltai‘ (Let’s bring a change). ‘Chalo Paltai‘ is also the brand philosophy of the channel.
Star Jalsha said that this new identity refresh will be backed with programming that reflects and reinforces its brand philosophy to further deepen its bond with the viewers.
The new logo shows the light and energy at the heart of the channel. It is also feminine yet powerful – a symbol of clarity and purity, denoting optimism and aspirations that every woman embraces as an inherent quality. The red swoosh signifies the strength and emotion that binds together. It is the colour of hope, desire, celebration, passion, love, and holiness.
Star Jalsha, which was launched on 8 September 2008, is soon going to complete four years. Shortly after the launch, it climbed the ratings ladder and is leading the genre with significant lead since then.
Star India president ad sales and Star Jalsha GM Kevin Vaz said, “Star Jalsha has become synonymous to Bengal with every step taken since its inception. It has embraced Bengal’s sentiments, aspirations, values and traditions in becoming a clear leader in the state’s entertainment scenario.”
On the new look, Vaz said, “This is about another beginning, of reinventing concepts, stories treatment and packaging, to keep up with changing emotions, societal changes and a fresh take on life and relationships.”
The brand refresh is being brought alive though a disruptive marketing strategy, both in terms of creativity and scale, covering an eclectic media mix of air, OOH, Print, Activation and Digital.
Vaz added that it will be for the first time in the history of regional television brands in India that a refresh is happening in such depth of detail, permeating to the core of its business.
“We have a huge outdoor plan. In a small state like West Bengal, we will have 500 hoardings. Apart from this, there will be branded trains, and all leading newspapers will have full page ads. The new look will also be promoted on the network channels,” he detailed.
Star Jalsha claims that its key shows like ‘Ekhane Aakash Neel‘, ‘Durga‘ and ‘Bandhan‘ have presented viewers with a myriad range of emotions by presenting a fresh perspective on life and relationships, living up to the brand philosophy and celebrating ”Notun Bangali” (new Bengal).
Meanwhile, the channel has also incorporated significant changes in the story lines of some of its shows including Maa, Ishtikutum and Tapur Tupur, to keep up with its tag line.
Additionally, it is also launching two new shows: Aanchal, s story that weaves the tale of a simple village girl who takes life head on and decides to bring justice to her family, and Care Kori Na, a coming of age love story in the backdrop of campus/college life.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
